Early treatment of highly active multiple sclerosis improves outcomes, according to research sponsored by Biogen.

Researchers compared 233 patients who began natalizumab within a year of the onset of MS symptoms with 179 and 144 patients who started it one to five years and more than five years after symptoms emerged. Over three years, the likelihood of worsening on the expanded disability status scale (EDSS), which assesses MS severity, did not differ significantly between the groups.

However, the likelihood of confirmed 24-week improvement in EDSS was significantly greater for those patients who received natalizumab within a year of MS symptoms emerging (49.3 per cent) than for those treated between one to five years (38.1 per cent) or more than five years (26.3 per cent) following symptom onset.

Natalizumab reduced the annualised relapse rate by about 93 per cent in all three groups.

The authors suggest that, “disability early in the course of MS may reflect inflammation that can be mitigated by timely treatment with natalizumab, whereas later disability may be more resistant to recovery”.

Recommended

Study highlights codeine dependence – a problem for pharmacy?

Pharmacies are a common source of codeine for dependent people but only one in 50 users seeks a pharmacist’s support

Statins cut CV mortality

Pravastatin reduces long-term cardiovascular mortality by more a quarter, even in men with markedly raised LDL-C levels

Popular

Building a nutritional foundation

This NPA-accredited module looks into the nutritional options available during an infant's first 1,000 days for mothers ...

Nutritional management of preterm infants

This NPA-accredited module looks into advising parents of preterm infants on their baby's unique nutritional needs to he...

Infant feeding and allergy risk

This NPA-accredited module highlights a clinically-proven hydrolysed formula that reduces the risk of developing allergi...